scholarly journals Circulating CD15 + LOX‐1 + PMN‐MDSCs are a potential biomarker for the early diagnosis of non‐small cell lung cancer

2021 ◽  
Author(s):  
Xinyu Tian ◽  
Ting Wang ◽  
Qisi Zheng ◽  
Yue Tao ◽  
Lei Dai ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Early Diagnosis ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Potential Biomarker

scholarly journals Circulating CD15+LOX-1+ PMN-MDSCs are a potential biomarker for the early diagnosis of non-small cell lung cancer

2020 ◽  
Author(s):  
Xinyu Tian ◽  
Ting Wang ◽  
Qisi Zheng ◽  
Yue Tao ◽  
Lei Dai ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Early Diagnosis ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Roc Curve ◽  
Small Cell ◽  
Cytokeratin 19 ◽  
Small Cell Lung ◽  
Potential Biomarker ◽  
Nsclc Patients

Aims: Non-small-cell lung cancer (NSCLC) is the most common clinical lung cancer. Polymorphonuclear-myeloid derived suppressor cells (PMN-MDSCs), which are the major population of MDSCs, are involved in NSCLC progression. Recently, it was found that lectin-type oxidized LDL receptor 1 (LOX-1) could identify humsn PMN-MDSCs. However, the role of CD15+LOX-1+ PMN-MDSCs in NSCLC early diagnosis has not been revealed. Here, we tried to confirm the application of the newly-identified CD15+LOX-1+ PMN-MDSCs in the early diagnosis of NSCLC. Methods: Flow cytometry (FCM) was used to detect the proportion of CD15+LOX-1+ PMN-MDSCs in the peripheral blood (PB) of healthy controls (HC) and NSCLC patients. The correlation of CD15+LOX-1+ PMN-MDSC frequency with levels of cytokeratin 19-fragments (CYFRA21-1), carcinoembryonic antigen (CEA), and carbohydrate antigen 125 (CA125) was analyzed. Receiver operating characteristic (ROC) curve was used to estimate the diagnostic efficacy of CD15+LOX-1+ PMN-MDSCs for NSCLC. Additionally, the association of CD15+LOX-1+ PMN-MDSC frequency with NSCLC prognosis/recurrence after surgery was explored. Results: The proportion of CD15+LOX-1+ PMN-MDSCs increased in PB of NSCLC patients. CD15+LOX-1+ PMN-MDSC proportion was positively correlated with levels of CEA and CYFRA21-1. The area under the ROC curve (AUC) of PMN-MDSC percentage was higher than CYFRA21-1, CEA and CA125. The proportion of CD15+LOX-1+ PMN-MDSCs decreased in patients after surgery. The frequency of CD15+LOX-1+ PMN-MDSCs was lower in NSCLC patients without recurrence compared to those with recurrence after surgery. Conclusions: Circulating CD15+LOX-1+ PMN-MDSCs are a potential diagnostic marker for NSCLC, and are associated with NSCLC prognosis and recurrence after surgery.

P60.01 Investigation of Aurora Kinase A as a Potential Biomarker of Radiation in Non-Small Cell Lung Cancer (NSCLC)

2021 ◽  
Vol 16 (10) ◽  
pp. S1163-S1164
Author(s):  
T. Mitchell ◽  
T. Jones ◽  
S. Danson ◽  
M. Glover ◽  
J. Bury ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Aurora Kinase ◽  
Small Cell ◽  
Small Cell Lung ◽  
Aurora Kinase A ◽  
Potential Biomarker ◽  
Kinase A

scholarly journals MODERN APPROACHES TO EARLY RADIOLOGICAL DIAGNOSIS OF BONE AND CEREBRAL METASTASES OF PERIPHERAL NON-SMALL CELL LUNG CANCER

2019 ◽  
pp. 71-76
Author(s):  
A. V. Laryukov ◽  
E. K. Laryukova ◽  
M. K. Mikhailov
Keyword(s):  
Lung Cancer ◽  
Early Diagnosis ◽  
Brain Metastases ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Cerebral Metastases ◽  
Diagnostic Methods ◽  
Small Cell Lung ◽  
Wide Range

Objective:сonstructive principles development of early diagnosis of bone and cerebral metastases of peripheral non-small cell lung cancer (PNSCLC), is based on the targeted preventive and personalized application of radiological and nuclear diagnostic methods.Materials and methods.There was performed the retrospective analysis of medical cards of 1473 patients with peripheral non-small cell lung cancer for the evaluation of the characteristics and frequency of bones and brain metastases. The frequency and features of bone and brain metastases depending on clinical and morphological features of the primary lung tumor were studied. 118 patients with PNSCLC with bone and brain metastases, regardless of clinical symptoms, were examined using a wide range of modern radiological and nuclear methods.Conclusion:the original algorithm has been developed on the study of the diagnostic significance of medical imaging methods. The application of this algorithm will significantly improve the early diagnosis of bone and cerebral metastases and improve the staging of PNSCLC.

scholarly journals In-house Implementation of Tumor Mutational Burden Testing to Predict Durable Clinical Benefit in Non-small Cell Lung Cancer and Melanoma Patients

Cancers ◽  
2019 ◽  
Vol 11 (9) ◽  
pp. 1271 ◽  
Author(s):  
Heeke ◽  
Benzaquen ◽  
Long-Mira ◽  
Audelan ◽  
Lespinet ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Clinical Benefit ◽  
Small Cell ◽  
Small Cell Lung ◽  
Mutational Burden ◽  
Potential Biomarker ◽  
Tumor Mutational Burden ◽  
Melanoma Patients

Tumor mutational burden (TMB) has emerged as an important potential biomarker for prediction of response to immune-checkpoint inhibitors (ICIs), notably in non-small cell lung cancer (NSCLC). However, its in-house assessment in routine clinical practice is currently challenging and validation is urgently needed. We have analyzed sixty NSCLC and thirty-six melanoma patients with ICI treatment, using the FoundationOne test (FO) in addition to in-house testing using the Oncomine TML (OTML) panel and evaluated the durable clinical benefit (DCB), defined by >6 months without progressive disease. Comparison of TMB values obtained by both tests demonstrated a high correlation in NSCLC (R2 = 0.73) and melanoma (R2 = 0.94). The association of TMB with DCB was comparable between OTML (area-under the curve (AUC) = 0.67) and FO (AUC = 0.71) in NSCLC. Median TMB was higher in the DCB cohort and progression-free survival (PFS) was prolonged in patients with high TMB (OTML HR = 0.35; FO HR = 0.45). In contrast, we detected no differences in PFS and median TMB in our melanoma cohort. Combining TMB with PD-L1 and CD8-expression by immunohistochemistry improved the predictive value. We conclude that in our cohort both approaches are equally able to assess TMB and to predict DCB in NSCLC.

scholarly journals Serum microRNA Signature Is Capable of Early Diagnosis for Non-Small Cell Lung Cancer

2019 ◽  
Vol 15 (8) ◽  
pp. 1712-1722 ◽  
Author(s):  
Xia Yang ◽  
Qiuhong Zhang ◽  
Ming Zhang ◽  
Wenmei Su ◽  
Zhuwen Wang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Early Diagnosis ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Serum Microrna

scholarly journals Detection of circulating genetically abnormal cells in peripheral blood for early diagnosis of non‐small cell lung cancer

2020 ◽  
Vol 11 (11) ◽  
pp. 3234-3242
Author(s):  
Wei‐Ran Liu ◽  
Bin Zhang ◽  
Chen Chen ◽  
Yue Li ◽  
Xin Ye ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Early Diagnosis ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Peripheral Blood ◽  
Small Cell ◽  
Small Cell Lung ◽  
Abnormal Cells
Sign in / Sign up

Export Citation Format

Share Document